Navigation Links
UltraShape Appoints Assaf Eyal as President & CEO
Date:8/26/2008

YOQNEAM, Israel and SAN RAMON, California, August 26 /PRNewswire/ -- UltraShape, the global leader in non-invasive fat reduction and body contouring, announced today the appointment of Assaf Eyal as President and Chief Executive Officer.

Assaf most recently served as Executive Vice President at NUR Macroprinters, a manufacturer of super-wide format digital printers and inks, While at NUR, Assaf was a member of a small leadership team that led to a successful sale to HP. Previously, he served in various positions at Orbotech Ltd., (NASDAQ: ORBK) over a seventeen year period, most recently as Co-President of the Display Division and Corporate VP, a division that grew under his leadership to revenues of $150 million. He holds a B.Sc in Engineering and M.Sc in Management.

Michael Berman, Chairman of the Board of UltraShape, stated, "Assaf's strong background in sales, marketing, service and R&D will enable him to strengthen UltraShape's position as market leader in the field of non-invasive body contouring. We are very pleased that he will be joining us and we believe that under his leadership UltraShape will reach important new achievements as it strives to enhance its market share and develop next generation body contouring products."

"I am pleased to join UltraShape as it strives to grow its leadership position in the industry," Assaf said. "The potential of working with a first-rate management team and a cutting-edge technology make this an exciting opportunity."

About the UltraShape(R) Contour I

The UltraShape Contour I system, which is authorized for marketing outside the U.S., incorporates patented non-thermal selective focused ultrasound technology. Contour I, is the first scientifically and clinical
'/>"/>

SOURCE UltraShape Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... The FBI recently approved the Promega Pow...ipating in or generating DNA records for the Natio...adison, WI USA (PRWEB) -- The FBI recently approve...e by laboratories participating in, or generating ...IS). NDIS currently contains more than seven milli...
(Date:11/24/2009)...vember24/PRNewswire-FirstCall/--Shireplc(LSE:SHP,...lcompany,today,announcedthatithassubmittedaMAAtoth...ompany,senzymereplacementtherapyindevelopment,fort...keting,applicationforvelaglucerasealfathathasbeens...andCanada. , Basedonaglobalsupplyshortageofth...
(Date:11/24/2009)...ly,November24/PRNewswire/--HealthRoboticstodayanno...groupofselected,investors.ThisrecentlyformedToront...csCanada,Inc.andwillmarket,install,andsupport,Heal...sthe,revolutionaryproductofferingsi.v.STATION(TM),...illalsoprovideassistanceonan"asneeded,basis"toitss...
(Date:11/24/2009)...ov.24/PRNewswire-FirstCall/--CellTherapeutics,Inc....21stAnnualPiperJaffrayHealthCareConference.Theconf...eHotel. ,, CTIwillpresentonTuesday,December1at1...ebcastofCTI,spresentationwillbeavailableat www.cel...ayafterwards. , ,PiperJaffrayHealthCareConference...
Breaking Biology Technology:NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...Pharma, Inc. (Nasdaq:,GORX) announced today that i...ts of its third fiscal quarter ended December 31, ...ET) with CEO, Mihir Taneja and VP/CFO,Carol Dore-F...erence call,by utilizing the following URL, http:/...?key=PVYY97BW8 thus,avoiding operator assistance ...
... Schering-Plough,Corporation (NYSE: SGP ) today ...on (FDA) has accepted the Peg-IFN (peginterferon a... (sBLA) for review and has,granted Priority Review...h,Stage III melanoma. Schering-Plough submitted it... The Priority Review designation is intended to ex...
...help doctors and clinicians identify best t...ease, BIRMINGHAM, Ala., Jan. 31 Clinical trial r...ation point to the need for more,detailed choleste...nd other,lipids. That,s according to Atherotech, a...xpanded cholesterol test called the VAP (Vertical ...
Other Biology Technology:GeoPharma Announces Third Quarter Conference Call 2FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 2FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 4FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 5FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 6Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 2Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 3
(Date:11/23/2009)...wa - The only swine vaccine available for the H1N1...ected with the virus. The vaccination marks the fi...gnosed with the pandemic flu., Iowa State Univer...eveloped the vaccine this summer and has been ship...Kansas and Illinois for several weeks., The late...
(Date:11/23/2009)... Ill. Two new studies reveal in unprecedented det...s to assemble new proteins and guide them toward t...used molecular dynamics flexible fitting (MDFF) to...prominent molecular partners. , The first study...ces , concerns the intimate signaling between the ...
(Date:11/23/2009)...al Institute of General Medical Sciences (NIGMS), ...s investing $42.3 million for grants in scientific..." NIH developed the GO grant program to stimulate ...ovided by the American Recovery and Reinvestment A...s that promise to have a significant impact on a f...
Breaking Biology News(10 mins):Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3SyntheMed Receives US Patent on Novel Polymer Technology 13286 1SyntheMed Receives US Patent on Novel Polymer Technology 13286 2Breakthrough Nursing Home Alternative Now Available to Cincinnati Elders and Their Families at Deupree Cottages 53216 1Breakthrough Nursing Home Alternative Now Available to Cincinnati Elders and Their Families at Deupree Cottages 53216 2Breakthrough Nursing Home Alternative Now Available to Cincinnati Elders and Their Families at Deupree Cottages 53216 3TriReme Medical Inc Receives CE Marking for Glider 28TM 29 PTCA Dilatation Catheter 53214 1TriReme Medical Inc Receives CE Marking for Glider 28TM 29 PTCA Dilatation Catheter 53214 2
...LA Research led by David Worthylake, PhD, Assista... at LSU Health Sciences Center New Orleans, may he...pound to prevent the spread of cancer. The researc...he Journal of Biological Chemistry . , During th...disease, cancer cells acquire the ability to detac...
...0 years it has become commonplace to think of Eart...tain equilibrium so that life might continue and f...ncient Greek goddess of Earth, even put forth the ...ganism, with its complex systems finely tuned to c...But actually it is the Gaia view that is out of ki...
...ms to forget things, will she end up demented? The...ms that may signal which 70-year-olds risk develop...t the Sahlgrenska Academy at the University of Got...y used to predict which elderly individuals risk d... The thesis shows that memory loss is the only fac...
Other Biology News:LSUHSC research describes function of key protein in cancer spread 2New book suggests Earth perhaps not such a benevolent mother after all 2New book suggests Earth perhaps not such a benevolent mother after all 3Early identification of dementia increasingly difficult 2
Murashige and Skoog basal salt solution with Gamborg's B5 vitamins, 10X concentrate from Research Organics, Inc.
...ing allows a high-throuput screening of a biologic...r artifitially induced changes in the expression l... studied, classified and compared to each other, c...tized scanning of the hybridized slides in Agilent...
Rabbit Anti-Esa1 Polyclonal Antibody, Unconjugated from Abcam
Goat Anti-Human RORgamma (S-14) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: